Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries

INTRODUCTION: The current study describes real-world clinical outcomes and factor usage among patients with haemophilia B switching from standard half-life factor IX (SHL FIX) treatment to recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis in European treatment centres. METHODS: This non-i...

Descripción completa

Detalles Bibliográficos
Autores principales: Funding, Eva, Lowe, Gillian, Poulsen, Lone H., Shapiro, Susan, Oldenburg, Johannes, Eriksson, Daniel, Falk, Aletta, Rich, Carly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427542/
https://www.ncbi.nlm.nih.gov/pubmed/37351812
http://dx.doi.org/10.1007/s12325-023-02559-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427542/
https://www.ncbi.nlm.nih.gov/pubmed/37351812
http://dx.doi.org/10.1007/s12325-023-02559-1

Ejemplares similares